A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders - PubMed (original) (raw)
Affiliations
- PMID: 2463930
A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders
N Shirafuji et al. Exp Hematol. 1989 Feb.
Abstract
[3H]thymidine uptake by NFS-60 cells in microcultures was found to increase in a linear fashion with the increasing doses of purified recombinant human granulocyte colony-stimulating factor (rhG-CSF). Such increases were found neither with rhG-CSF samples pretreated with rabbit anti-rhG-CSF serum nor with other human colony-stimulating factors such as granulocyte-macrophage colony-stimulating factor (hGM-CSF) or macrophage colony-stimulating factor (hM-CSF). Based on these findings, sera from normal persons and patients with severe infections or various hematological disorders were tested after dialysis using this system in order to determine whether G-CSF levels in sera can be estimated or not. In ten normal persons, five patients with acute myelogenous leukemia (AML M1, M2, and M3), five with myelodysplastic syndrome, and four with chronic myelogenous leukemia, no increases in [3H]thymidine uptake were found within the dose range of 0.4 microliters to 50 microliters. In contrast, linear dose responses parallel to a G-CSF standard curve were observed in one patient with a severe bacterial infection, four with aplastic anemia, two with acute myelomonocytic leukemia (AMMoL) (M4), and two with idiopathic neutropenia tested. From the standard curve, the probable levels of G-CSF were calculated as follows: approximately 200 pg/ml with infection, 130-220 pg/ml with aplastic anemia, 150 and 200 pg/ml with AMMoL, and 1120 and 1200 pg/ml with idiopathic neutropenia. The activities of sera were reduced by the anti-rhG-CSF serum pretreatment in the same way as documented in the case of rhG-CSF. Furthermore, the level in a patient with a severe infection became undetectable soon after elimination of the infection and blood neutrophil counts had returned to normal. These findings indicate that the microbioassay system will be useful for measuring circulating G-CSF levels which would fluctuate in accord with requirements for stimulating neutrophil production or with abnormal production of hG-CSF.
Similar articles
- Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study.
Teshima H, Ishikawa J, Kitayama H, Yamagami T, Hiraoka A, Nakamura H, Shibata H, Masaoka T, Takaku F. Teshima H, et al. Exp Hematol. 1989 Sep;17(8):853-8. Exp Hematol. 1989. PMID: 2475358 - Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats.
Fulton R, Gasper PW, Ogilvie GK, Boone TC, Dornsife RE. Fulton R, et al. Exp Hematol. 1991 Sep;19(8):759-67. Exp Hematol. 1991. PMID: 1714401 - [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
Borota R, Borota J, Belić A, Gebauer E, Stefanović N. Borota R, et al. Med Pregl. 1997 Mar-Apr;50(3-4):87-93. Med Pregl. 1997. PMID: 9229690 Review. Croatian. - The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL, Negrin R, Nagler A. Greenberg PL, et al. Cancer Surv. 1990;9(1):199-212. Cancer Surv. 1990. PMID: 2276114 Review.
Cited by
- Semisynthesis of Homogeneous, Active Granulocyte Colony-Stimulating Factor Glycoforms.
Kerul L, Schrems M, Schmid A, Meli R, Becker CFW, Bello C. Kerul L, et al. Angew Chem Int Ed Engl. 2022 Sep 26;61(39):e202206116. doi: 10.1002/anie.202206116. Epub 2022 Aug 25. Angew Chem Int Ed Engl. 2022. PMID: 35853828 Free PMC article. - GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX, Wang F, Guo ZX, Hu Y, An SN, Luo M, Zhang H, Wu SC, Huang HQ, Fu LW. Rong QX, et al. Mol Cancer. 2021 May 29;20(1):80. doi: 10.1186/s12943-021-01374-y. Mol Cancer. 2021. PMID: 34051805 Free PMC article. - Synthesis and Biological Evaluation of a Degradable Trehalose Glycopolymer Prepared by RAFT Polymerization.
Lau UY, Pelegri-O'Day EM, Maynard HD. Lau UY, et al. Macromol Rapid Commun. 2018 Mar;39(5):10.1002/marc.201700652. doi: 10.1002/marc.201700652. Epub 2017 Dec 18. Macromol Rapid Commun. 2018. PMID: 29251372 Free PMC article. - Substituted Polyesters by Thiol-Ene Modification: Rapid Diversification for Therapeutic Protein Stabilization.
Pelegri-O'Day EM, Paluck SJ, Maynard HD. Pelegri-O'Day EM, et al. J Am Chem Soc. 2017 Jan 25;139(3):1145-1154. doi: 10.1021/jacs.6b10776. Epub 2017 Jan 12. J Am Chem Soc. 2017. PMID: 28079370 Free PMC article. - Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected Peptides.
Roberts AG, Johnston EV, Shieh JH, Sondey JP, Hendrickson RC, Moore MA, Danishefsky SJ. Roberts AG, et al. J Am Chem Soc. 2015 Oct 14;137(40):13167-75. doi: 10.1021/jacs.5b08754. Epub 2015 Oct 1. J Am Chem Soc. 2015. PMID: 26401918 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical